Navigation Links
GEA Process Engineering and G-CON Manufacturing Announce PCMM Collaboration with Pfizer
Date:9/24/2013

(PRWEB) September 24, 2013

GEA Process Engineering and G-CON Manufacturing announced today that they have entered into a PCMM (Portable Continuous Miniature & Modular) manufacturing collaboration with Pfizer Inc. with the aim of developing the next generation of oral solid dose (OSD) processing technologies to address the rapidly changing requirements of pharmaceutical development and manufacturing. This collaboration brings together three companies with leading capabilities in product development and manufacturing, OSD processing equipment, and portable, self-contained Good Manufacturing Practice (GMP) facility modules, known as “PODs.” A preliminary engineering study has already been completed, and the new collaboration will focus on the fabrication and qualification of a prototype unit.

“We are very enthusiastic to be working with Pfizer, a leading multinational pharmaceutical corporation, and G-CON to develop a turnkey solution for a continuous and portable manufacturing system,” says Jan Vugts, Managing Director, GEA Pharma Systems. “This project is another milestone in the advancement of the GEA Process Engineering Continuous Manufacturing activities in pharmaceuticals. It builds on the experience of Pfizer and GEA in Real Time Release and has the capability to set the next standard for OSD manufacturing.”

The goal of the collaboration is to create a system that integrates small footprint, continuous/semi-continuous processing equipment, smart control systems, and PODs to process active pharmaceutical ingredient (API) powders and inactive ingredients through to bulk tablets or capsules. PODs, which are portable and can be rapidly deployed, are a cost-effective alternative to large, highly capitalized manufacturing facilities with fixed equipment and limited flexibility. "G-CON's team is very excited to be part of this project and to again demonstrate the flexibility and quality of our autonomous cleanroom POD systems, this time in a solid dosage form application," states Maik Jornitz, Chief Operating Officer, G-CON Manufacturing LLC. "We are privileged to work with Pfizer and GEA and look forward to achieving the goals of the consortium."

This first-of-a-kind system would have the potential to transform the future of pharmaceutical process development and manufacturing while providing the flexibility needed to address the evolving portfolio requirements for in-country and small-lot manufacturing. Additionally, it would have the potential to allow product development, clinical supply manufacture, and commercialization to take place using identical processing equipment, thereby simplifying process transfer, eliminating scale-up and significantly reducing API consumption during the development process. The platform would ultimately have the potential to support a fast-response, low- inventory supply chain as well.

Upon successful completion of this initiative, GEA and G-CON will work with Pfizer to deploy this complete solution of components and the POD facility globally.

“This new OSD manufacturing paradigm will achieve significant cost savings and simplified technology transfer/scale-up from R&D to commercial manufacturing,” said Rod MacKenzie, Senior Vice President and Head of PharmaTherapeutics R&D at Pfizer. “Using the same equipment for development, clinical supplies, and commercial production is expected to maximize efficiencies in manufacturing across the enterprise.”

To more rapidly advance and develop this vision, Pfizer, GEA and G-CON will further explore opportunities to partner with additional, interested companies.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11155867.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Aurora Clinic Now Offering Simplified Process for Medical Marijuana Qualification
2. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
3. Natural Acne Remedy, Probiotic Action Shares Industry Insight on the Correlation between Processed Foods and Acne
4. White Mountain Process' New Whisper Technology Creates World's Only Squeal-less Mechanical Seal
5. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
6. Process Analytical Technology/Quality by Design – Keeping An Eye on Your Quality, New Life Science Webinar Hosted by Xtalks
7. Genedata at ESACT Announces Expansion Into Biopharma Process Development
8. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
9. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
10. New 1-step process for designer bacteria
11. Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of ... Assay from Salimetrics’ SalivaLab , the relationship between insulin and other relevant ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):